In this study, we investigated the therapeutic effects of MDRmiRs for the enhancement of chemotherapeutics using a glioma cell line (T98G) with high MGMT expression and a triple-negative breast cancer cell line (MDA-MB-231-luc) with high ABCB1 expression. The gene discussed is MGMT; the disease is glioma.